2012-08-27T12:09:16-05:00 2011-12-31 582676261 Rogers & Company PLLC 8300 Boone Boulevard Suite 600 Vienna VA 22182 990 2011-01-01 061389829 Albert B Sabin Vaccine Institute Inc ALBE 2028428610 2000 Pennsylvania Avenue NW No 7100 Washington DC 20006 Michael W Marine 2028428610 2012-08-27 1 Nicole M Simon CPA P01315245 7038930300 2012-08-16 2011 2016-02-24 21:20:13Z Michael W Marine 2000 Pennsylvania Avenue NW No 7100 Washington DC 20006 22291681 0 X www.sabin.org X 1994 MD An organization of scientists, researchers and advocates for a world free of needless suffering. 12 9 68 0 0 0 21076480 22266964 0 0 25207 24717 0 0 21101687 22291681 7920650 11186989 0 0 3791300 4720439 720011 122195 352469 4473509 8672834 16905470 24702457 4196217 -2410776 26815225 25035530 3620662 4617860 23194563 20417670 X To reduce needless human suffering from vaccine preventable and neglected tropical diseases through innovative vaccine research and development; and to advocate for improved access to vaccines and essential medicines for citizens around the globe. 0 0 6733653 3662099 Sabin Vaccine Insitute Product Development Partnership (Sabin PDP)The Sabin PDP made significant progress in 2011, marking our 11-year anniversary of the program.Human Hookworm Vaccine InitiativeThe Sabin PDP's vaccine development pipeline includes a bivalent recombinant protein vaccine, Na-GST-1 and Na-APR-1, formulated with Alhydrogel +/-, a synthetic lipid A immunostimulant. Following regulatory approval in the U.S. (FDA) and Brazil (ANVISA), Phase 1 testing in Brazil began in 2011.Schistosomiasis Vaccine InitiativeThe Sabin PDP completed manufacture of the schistosomiasis vaccine in December 2011, expressing the antigen Sm-TSP-2, and is completing release testing of the vaccine for a planned potency and toxicology study in preparation for regulatory filing and clinical trials. Chagas Vaccine InitiativeA prototype vaccine comprised of two lead candidate antigens (Tc24 and TSA-1) is under early stage development and preclinical testing at the Sabin Vaccine Institute and Texas Children's Hospital Center for Vaccine Development in Houston, Texas. 10946619 6829675 Global Network for Neglected Tropical Diseases Program - The Global Network for Neglected Tropical Diseases (Global Network) is dedicated to raising the awareness, political will, and funding necessary to control and eliminate the seven most common neglected tropical diseases (NTDs) - a group of disabling, disfiguring, and deadly diseases affecting more than 1.4 billion people worldwide living on less than $1.25 a day. In collaboration with the World Health Organization (WHO), national health ministries, international organizations, pharmaceutical companies, donors and affected communities, the Global Network strives to control and eliminate these diseases of poverty by 2020. In order to accomplish this, The Global Network develops coordinated advocacy and resource mobilization activities and promotes NTD control through integrated mass drug administration (MDA) according to guidelines set by the WHO. We also advocate for NTD control programs that have been integrated into existing delivery systems, including immunization campaigns, Child Health Days, school health programs, and Vitamin A campaigns. We have helped to create regional funding mechanisms that support these NTD control and elimination programs and seek to leverage cross-sectoral investments in water and sanitation, and other development and poverty reduction projects for a comprehensive approach to disease control efforts. The Global Network's advocacy efforts include appealing for increased funding of NTD projects by the U.S. and UK governments, and building awareness of NTDs through media placements, speeches, and educational visits. 5068755 633392 Vaccine Advocacy and Education Programs - The Sabin Vaccine Institute's Vaccine Advocacy and Education program works together with leading health experts and organizations to promote awareness and increased utilization of both existing and new, underutilized vaccines. In 2011, we held various events, including a journalist information session and vaccinology course, to discuss relevant research and updates that informed public health agendas related to rotavirus, meningococcal, typhoid fever, pertussis, rubella, and pneumococcal disease. We marked the launch of the Dengue Vaccine Initiative in 2011, a global partnership with governments, industry, and the scientific community, to increase the priority given to dengue vaccines at the global level. The Sabin Vaccine Institute is responsible for the Communication and Advocacy needs of this initiative.The Sustainable Immunization Financing (SIF) program operates in twelve African, and three Asian, pilot countries on advocacy-driven initiatives for sustainable immunization financing. SIF invites key stakeholders, parliamentarians, and members of ministries of health and finance to develop innovative financing solutions that sustain vital public health programs. Outputs from such meetings have ranged from declarations and ideas for tax-devoted funding to conceiving financing mechanisms, all in support of this initiative.The Coalition against Typhoid (CaT) Secretariat was founded in September 2010. The Secretariat's purpose is to facilitate progress towards the CaT goal of expediting and sustaining evidence-informed decisions regarding the use of typhoid vaccination to prevent childhood enteric fever. Participation in the coalition is open to institutions that contribute to the prevention and control of enteric fever and includes over 25 organizations as of 2012, including the World Health Organization (WHO), UNICEF, Oxford University and the Wellcome Trust and the Wellcome Trust Sanger Institute. 22749027 1 1 0 0 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 1 1 0 1 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 26 0 68 1 0 0 0 0 0 0 0 0 0 0 X 12 9 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 MD DC NY X X The Organization 2028428610 2000 Pennsylvania Avenue NW No 7100 Washington DC 20006 Louis Cooper 1.00 X 0 0 0 Allan Goldstein 1.00 X 0 0 0 Helene Hayman 1.00 X 0 0 0 Axel Hoos 1.00 X 0 0 0 Mort Hyman 20.00 X X 0 0 0 Kevin Reilly 1.00 X 0 0 0 Gary Rosenthal 1.00 X 0 0 0 Phillip Russell 5.00 X 39050 0 0 Marc Shapiro 1.00 X 0 0 0 Alisa Swidler 1.00 X 0 0 0 Peter Thoren 1.00 X 0 0 0 Mike Whitman 1.00 X X 0 0 0 Mark Kline 1.00 X 0 0 0 Paul Klotman 1.00 X 0 0 0 Michael Marine 40.00 X X 273965 0 12370 Peter Hotez 20.00 X X 55833 0 0 Ciro de Quadros 40.00 X X 333661 0 1444 Brian Davis 40.00 X 208874 0 23365 Neeraj Mistry 40.00 X 229877 0 4604 Michael McQuestion 40.00 X 168068 0 21944 Christopher Nelson 40.00 X 160617 0 20923 Marva Loblack 40.00 X 135893 0 17428 David Diemert 40.00 X 167965 0 10569 1773803 0 112647 12 0 1 0 Changing our World 220 East 42nd St 5th Flr New York NY 10017 NTD resource development 1100064 Fraunhofer USA Inc 44792 Helm Street Plymouth MI 48170 Vaccine manufacture 475338 Wunderman Greater London House Hampstead Roa London UK NTD advocacy 415605 AERAS Global TB Vaccine Foundation 1405 Research Blvd Rockville MD 20850 Vaccine manufacture 375000 Boston Consulting Group PO Box 75200 Chicago IL 60675 SIF program review 338000 13 22266964 4822 22266964 24717 24717 22291681 0 0 24717 4876117 4876117 6310872 6310872 948562 749546 166168 32848 3131362 2484842 539869 106651 72017 55610 13666 2741 301677 232946 57248 11483 266821 216904 41462 8455 43996 37432 6564 13000 11060 1940 122195 122195 4221098 4147925 73173 1355582 1314660 36280 4642 318977 259916 50747 8314 16217 7705 8396 116 523153 58853 464300 893759 836772 13356 43631 1065336 1032979 22869 9488 2203 855 1346 2 19712 19712 86305 26315 59990 Dues and subscriptions 39015 33056 4377 1582 Foreign exchange loss 27963 27963 Recruiting 27387 19022 8261 104 Miscellaneous 13857 3688 9952 217 5274 3989 1285 24702457 22749027 1600961 352469 24339796 22158396 2286100 2432250 3709 57331 97680 268383 288547 203452 39067 85095 48873 34075 26815225 25035530 2937947 3956238 472376 445113 210339 216509 3620662 4617860 X 1806523 1982925 21388040 18434745 23194563 20417670 26815225 25035530 X -2410776 -366117 X X 0 1 1 X 0 X 15829944 25512242 17123901 21076480 21900847 101443414 15829944 25512242 17123901 21076480 21900847 101443414 75396065 26047349 390893 241594 92623 25207 24717 775034 102218448 632005 0.25480 0.21890 X The Organization has maintained a continuous and bona fide program for solicitation of funds from the general public, community, government units, and other charities. The public support percentage for 2011 and 2010 was approximately 26% and 22%, respectively, since some donations for use in the Organization's charitable programs from several contributors were larger than anticipated. As contained in the program descriptions in Part III of the Form 990, the Organization's program services directly benefit the general public on a continuing basis. While certain large Foundation grants may continue in the near term, this support is crucial to the Organization's exempt purpose of promoting and contributing to the control of infectious and neglected tropical diseases. The Organization expects to continue to solicit qualifying public support to assist in carrying out these program. Finally, the Organization's governing body represents the broad interest of the public, with no one individual or related group of individuals having undue control or influence over the Organization's funding or affairs. These Board members bring important skill sets and qualifications that help the Organization plan and achieve its strategic objectives. Accordingly, the "facts and circumstances" substantiate that the Organization continues to operate as a public charity. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 0 288547 203452 85095 0 85095 Obligation under capital lease 10032 Deferred rent 206477 216509 22291681 24702457 -2410776 -366117 -366117 -2776893 22189173 263609 -366117 -102508 22291681 0 22291681 24966066 263609 263609 24702457 0 24702457 Description of Uncertain Tax Positions Under FIN 48: Part X: The Organization has no significant uncertain tax positions during the year ended December 2011. Part XI, Line 8 - Other Adjustments: Refunded contributions -366,117. Part XII, Line 2d - Other Adjustments: Refunded contributions -366,117. 1 Sub-Saharan Africa 0 0 Grants to recipients located in region. 1200000 Europe (Including Iceland & Greenland) 0 0 Grants to recipients located in region. 3606886 South America 0 0 Grants to recipients located in region. 896262 East Asia and the Pacific 0 0 Grants to recipients located in region. 607724 0 0 0 0 0 0 6310872 0 6310872 Sub-Saharan Africa NTD Control 1200000 EFT Europe (Including Iceland & Greenland) - NTD Control 263254 EFT South America - Argentina, Bolivia, Vaccine Development 896262 EFT East Asia and the Pacific - Vaccine Development 122389 EFT Europe (Including Iceland & Greenland) - NTD Control 302047 EFT East Asia and the Pacific - NTD Control 224305 EFT East Asia and the Pacific - NTD Control 261030 EFT Europe (Including Iceland & Greenland) - Vaccine Development 376000 EFT Europe (Including Iceland & Greenland) - NTD control 2665585 EFT 9 0 0 0 0 0 0 0 Procedure for Monitoring Grants Outside the U.S.: Schedule F, Part I, Line 2: All grants are monitored in several ways. First, there is a due diligence process in awarding the grant followed by an executed agreement with a scope of work. Typically, payments are sent either when milestones are met or in accordance with an established payment schedule. Second, the Organization requires monthly, quarterly, and/or annual financial reports from recipients prior to sending the subsequent payment. Third, and as needed, the Organization performs site visits. And finally, if deemed necessary, the Organization has a third party review the program impact and/or accounting records of the recipient(s). X X X X X X 1 Changing Our World 220 East 42nd St 5th Floor New York NY 10017 Development strategy and outreach 0 232399 122195 110204 232399 122195 110204 DC MD NY 1 Centers for Disease Control & Prevention PO Box 15580 Atlanta GA 30333 262240 Advocacy for control of Pertussis Earth Institute Columbia University 1210 Amsterdam Ave New York NY 10027 135598093 501(c)(3) 101015 NTD Control Baylor College of Medicine 1 Baylor Plaza Houston TX 77030 741613878 1213854 Vaccine Development IMA World Health 213 Main Street NW New Windsor MD 21776 65197 NTD Control Pan America Health Organization 525 23rd Street NW Washington DC 20037 492394 NTD Control The George Washington University 2300 I Street NW Washington DC 20147 530196584 501(c)(3) 1390299 Vaccine Development Inter-American Development Bank 1300 New York Ave NW Washington DC 20577 1250000 NTD Control The Universtiy of Kansas Center for Research 2385 Irving Hill Road Lawrence KS 66045 480680117 101118 Vaccine Development 2 6 Procedure for Monitoring Grants in the U.S.: Part I, Line 2: Schedule I, Part I, Line 2: All grants are monitored in several ways. First, there is a significant due diligence process in awarding the grant followed by an executed agreement with a scope of work. Typically, payments are sent either when milestones are met or in accordance with an established payment schedule. Second, the Organization requires monthly, quarterly, and/or annual financial reports from recipients prior to sending the subsequent payment. Third, and as needed, the Organization has site visits. Finally, if deemed necessary, the Organization has a third party review the accounting records of the recipient(s). X X X X X 0 0 0 0 0 0 0 0 0 Michael Marine 248965 0 25000 0 0 0 10000 0 2370 0 286335 0 0 0 Ciro de Quadros 298661 0 35000 0 0 0 0 0 1444 0 335105 0 0 0 Brian Davis 193874 0 15000 0 0 0 8000 0 15365 0 232239 0 0 0 Neeraj Mistry 222377 0 7500 0 0 0 0 0 4604 0 234481 0 0 0 Michael McQuestion 168068 0 0 0 0 0 6773 0 15171 0 190012 0 0 0 Christopher Nelson 160617 0 0 0 0 0 6033 0 14890 0 181540 0 0 0 Marva Loblack 131893 0 4000 0 0 0 4900 0 12528 0 153321 0 0 0 David Diemert 154237 0 13728 0 0 0 5406 0 5163 0 178534 0 0 0 Form 990, Part VI, Section B, line 11 The Form 990 is prepared by an outside tax accountant. It is first reviewed by the Chief Operating Officer and then presented to the Finance Committee for their review and approval. Finally, it is presented to the full Board of Trustees for their review and approval before filing. Form 990, Part VI, Section B, line 12c The Organization's Ethics & Compensation Committee is responsible for ensuring the conflict of interest policy is up-to-date and adhered to by the Trustees. Form 990, Part VI, Section B, line 15 Compensation of officers and/or key employees is set in consultation with the Compensation and Ethics Committee. The Organization uses a mix of data points including: independent salary surveys; comparable pay by similar organizations; compensation consultant and its own internal pay scale. Form 990, Part VI, Section C, line 19 The Organization's financial statements are included on its website. Also, the Organization's governing documents and conflict of interest policy are available upon request. Changes in Net Assets or Fund Balances: Form 990, Part XI, line 5: Refunded contributions -366,117. Total to Form 990, Part XI, Line 5: -366,117. Form 990, Part XII, Line 2c: The Organization has a finance committee that assumes responsibility for oversight of the audit. This process is consistent with prior years.